The Recovery At PaySign Has Legs
The company spent the pandemic years in the wilderness as blood donors stayed away and their accounting for brokerage from pharma programs was overly aggressive. But the company kept on […]
The company spent the pandemic years in the wilderness as blood donors stayed away and their accounting for brokerage from pharma programs was overly aggressive. But the company kept on […]
The company had a stellar year with 48% revenue growth, margin expansion and a profit explosion. Some worries emerged about the company’s financial control mechanisms and the impact of COVID-19, […]
PaySign is fast growing, profitable and generates cash, and the growth is set to continue for the foreseeable future. The company leverages its core capabilities in new segments and expands […]
Priced for perfection, investors were getting scared by a restricted cash issue and a downward revenue guidance, and the shares fell almost 50%. On closer inspection we don’t think these […]
There seems to be a mass rotation out of high valued growth companies, in particular those which largely depend on SaaS business models. These rotations usually last longer than just […]
The advantage of having your own payments platform is that it can be leveraged, and this is what the company is doing. It started in one vertical, plasma with fairly […]